# A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

> **NCT02308020** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 162 (actual)

## Conditions studied

- Breast Cancer
- Non-small Cell Lung Cancer
- Melanoma
- Brain Metastases

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT02308020
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-20
- **Primary completion:** 2018-11-08
- **Final completion:** 2019-11-08
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02308020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02308020, "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02308020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*